BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Zugocabtagene geleucel readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of Zugocabtagene geleucel\, from ClinicalTri
 als.gov estimates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT07804004-5691@assetmemo.bio
DTSTAMP:20261121T005642Z
DTSTART;VALUE=DATE:20291230
DTEND;VALUE=DATE:20291231
SUMMARY:Zugocabtagene geleucel: Phase 1/2 readout est. (NCT07804004)
DESCRIPTION:Zugocabtagene geleucel\, phase 1/2.\nStudy: A Safety and Effica
 cy Study Evaluating CTX112 in Subjects With Refractory Neurologic Autoimmu
 ne Disease\nEstimated primary completion: 30 December 2029. This is a Clin
 icalTrials.gov estimate\, not a confirmed readout date\, and it can move.\
 nDrug page: https://assetmemo.bio/drug/zugocabtagene-geleucel#upcoming-eve
 nts\nRegistry record: https://clinicaltrials.gov/study/NCT07804004
URL:https://assetmemo.bio/drug/zugocabtagene-geleucel#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05643742-5691@assetmemo.bio
DTSTAMP:20261121T005642Z
DTSTART;VALUE=DATE:20300131
DTEND;VALUE=DATE:20300201
SUMMARY:Zugocabtagene geleucel: Phase 1/2 readout est. (NCT05643742)
DESCRIPTION:Zugocabtagene geleucel\, phase 1/2\, Follicular Lymphoma.\nStud
 y: A Safety and Efficacy Study Evaluating CTX112 in Subjects With Relapsed
  or Refractory B-Cell Malignancies\nEstimated primary completion: January 
 2030. This is a ClinicalTrials.gov estimate\, not a confirmed readout date
 \, and it can move.\nDrug page: https://assetmemo.bio/drug/zugocabtagene-g
 eleucel#upcoming-events\nRegistry record: https://clinicaltrials.gov/study
 /NCT05643742
URL:https://assetmemo.bio/drug/zugocabtagene-geleucel#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06925542-5691@assetmemo.bio
DTSTAMP:20261121T005642Z
DTSTART;VALUE=DATE:20311231
DTEND;VALUE=DATE:20320101
SUMMARY:Zugocabtagene geleucel: Phase 1 readout est. (NCT06925542)
DESCRIPTION:Zugocabtagene geleucel\, phase 1\, Systemic Lupus Erythematosus
 .\nStudy: A Safety and Efficacy Study Evaluating CTX112 in Adult Subjects 
 With Refractory Autoimmune Disease\nEstimated primary completion: 31 Decem
 ber 2031. This is a ClinicalTrials.gov estimate\, not a confirmed readout 
 date\, and it can move.\nDrug page: https://assetmemo.bio/drug/zugocabtage
 ne-geleucel#upcoming-events\nRegistry record: https://clinicaltrials.gov/s
 tudy/NCT06925542
URL:https://assetmemo.bio/drug/zugocabtagene-geleucel#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07549698-5691@assetmemo.bio
DTSTAMP:20261121T005642Z
DTSTART;VALUE=DATE:20331231
DTEND;VALUE=DATE:20340101
SUMMARY:Zugocabtagene geleucel: Phase 1/2 readout est. (NCT07549698)
DESCRIPTION:Zugocabtagene geleucel\, phase 1/2.\nStudy: Safety and Prelimin
 ary Efficacy of CTX112 in Adult Participants With Relapsed/Refractory Hema
 tologic Autoimmune Disease\nEstimated primary completion: December 2033. T
 his is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and 
 it can move.\nDrug page: https://assetmemo.bio/drug/zugocabtagene-geleucel
 #upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT075
 49698
URL:https://assetmemo.bio/drug/zugocabtagene-geleucel#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
